The Power of
Regenerative Ophthalmology

We are developing innovative new therapies to treat vision loss with the mission of improving the quality of life for millions of patients worldwide.

Human Retinal Pigment Epithelial Cells

We believe in the power of vision. Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technologies. The company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration. Ocata’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

View our current Ocata Corporate Presentation

Download the PDF

Retina, 900x maginified

Vision Rules the Brain: 90% of information that comes to the brain is visual.

Our leading scientists collaborate with a global network of experts to further the field of Regenerative Therapeutics™.

Learn more »